Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial

Painful Bladder Infections and a New Way to Treat Them

Cystitis—bladder infection—is so common that roughly half of all women will experience it at least once, and many suffer repeated bouts that disrupt work, sleep and daily life. Today’s standard treatment is antibiotics, but rising antibiotic resistance and frequent recurrences mean relief is often temporary. This study tests a very different idea: instead of attacking the bacteria directly, what if we calm the body’s own overzealous defense system and let it restore balance?

Why Bladder Infections Keep Coming Back

Acute cystitis happens when bacteria, most often Escherichia coli from the gut, climb into the bladder and trigger burning, urgency and pelvic pain. For many women, these infections return again and again, despite standard care. Surveys show that up to a third of patients experience recurrences, and many still have bothersome symptoms after treatment. At the same time, the bacteria that cause urinary tract infections are becoming increasingly resistant to antibiotics. Doctors and patients therefore need alternatives that can ease symptoms, prevent recurrences and reduce antibiotic use.

Turning Down the Body’s Alarm System

Recent laboratory research has revealed that an overactive alarm signal in the immune system, driven by a molecule called interleukin‑1, can make cystitis worse. In mice, blocking the receptor for this signal with a drug called anakinra reduced inflammation and helped clear bacteria as effectively as antibiotics. Building on those findings, the current clinical trial enrolled 30 adult women with a history of recurrent cystitis who arrived at a clinic with a new, clearly defined episode. They were randomly assigned to receive either anakinra injections once daily for five days or the commonly used antibiotic nitrofurantoin by mouth for the same period. Symptom severity, quality of life, urine tests and blood markers were followed for six months.

How the Two Treatments Performed

Both groups felt noticeably better after just five days. Using a standardized symptom checklist that scores burning, urgency, frequency, pain and visible blood in urine, nearly all women in both groups showed large drops in symptom scores, and about two‑thirds reported that most or all of their symptoms were gone. Improvements in comfort, daily activities and social life closely paralleled these changes and remained evident at 15 days, 30 days and even six months. The number of new infections over the six months after treatment was clearly lower than in the six months before the trial, whether women had received anakinra or nitrofurantoin. Urine cultures showed that both treatments reduced bacterial counts over time, and a focused analysis of women who started out with very high bacterial levels confirmed that symptom relief and better quality of life did not depend on an immediate, complete wipe‑out of the bacteria.

What Immune‑Focused Therapy Adds

While symptom relief and recurrence rates were similar between groups, their immune signatures told a different story. In women treated with anakinra, gene activity patterns in blood cells shifted within two days, showing a broad dampening of inflammatory pathways—including those tied to so‑called "cytokine storms"—and reduced counts of certain white blood cells. These changes were not seen in the antibiotic group, where immune activity looked largely unchanged. Importantly, treatment lasted only five days, and by later follow‑up there was no sign of persistent immune suppression. Side effects in both groups were mild and infrequent; no serious events occurred, and no one had to stop treatment.

What This Could Mean for Patients

The trial suggests that short‑term, targeted calming of the innate immune response can ease pain and urgency from recurrent cystitis just as well as a standard antibiotic, while also dialing down the broader inflammatory burden that may underlie lingering discomfort between attacks. If larger studies confirm these results, immune‑modulating therapy like anakinra could offer some women a way to treat bladder infections and reduce recurrences without always reaching for antibiotics—helping both individual patients and the wider fight against antibiotic resistance.

Citation: Ambite, I., Pilatz, A., Buch-Heberling, M. et al. Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial. Nat Microbiol 11, 638–647 (2026). https://doi.org/10.1038/s41564-026-02262-1

Keywords: urinary tract infection, cystitis, immune therapy, antibiotic alternative, women’s health